Anchorage, AKNCT05040360Now EnrollingIRB Ready

Pancreatic Neuroendocrine Tumors Clinical Trial in Anchorage, AK

Access cutting-edge pancreatic neuroendocrine tumors treatment through this clinical trial at a research site in Anchorage. Study-provided care at no cost to qualified participants.

Sponsored by SWOG Cancer Research Network

Quick Self-Assessment

See if you qualify for this Anchorage location

Preparing your pre-screening questions...

Expert Care in Anchorage

Access pancreatic neuroendocrine tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreatic neuroendocrine tumors treatment provided free

Apply for This Anchorage Location

Check if you qualify for this pancreatic neuroendocrine tumors clinical trial in Anchorage, AK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Anchorage

    Convenient for AK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Anchorage site if eligible
  4. 4Begin participation

About This Pancreatic Neuroendocrine Tumors Study in Anchorage

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients wit

Sponsor: SWOG Cancer Research Network

Who Can Participate

Inclusion Criteria

Participants must have a histologic diagnosis of well-differentiated pancreatic neuroendocrine tumor (pNET) that was resected between 14 and 90 days prior to registration. Participants must have a scan within 90 days prior to registration without evidence of metastatic disease. Acceptable scans are multiphase computed tomography (CT) abdomen, magnetic resonance imaging (MRI) with intravenous (IV) contrast of the abdomen, or positron emission tomography (PET)-CT DOTATATE imaging if the DOTATATE PET-CT included IV iodine contrast for the CT portion of the exam
Resection must have been an R0 or R1 per treating investigator's assessment and/or pathology report
Ki-67 testing, which is considered part of standard of care in the pathology report, must have been performed between 14 and 90 days prior to registration and the result must be \>= 3% and =\< 55%. Treating investigators are encouraged to contact the S2104 Study Chairs and/or the study pathology chair with

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Anchorage?

Yes, this clinical trial (NCT05040360) has an active research site in Anchorage, AK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Neuroendocrine Tumors Treatment Options in Anchorage, AK

If you're searching for pancreatic neuroendocrine tumors treatment options in Anchorage, AK, this clinical trial (NCT05040360) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Anchorage research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic neuroendocrine tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic neuroendocrine tumors clinical trials near you to find additional studies recruiting in your area.

More Neuroendocrine Tumors Trials in Anchorage, AK

See all neuroendocrine tumors clinical trials recruiting in Anchorage — not just this study.

Browse Neuroendocrine Tumors Trials in Anchorage

Ready to Join in Anchorage?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Anchorage, AK